Prof Wildiers talks to ecancertv at SABCS 2015 about the final overall survival (OS) results from the a randomized, open-label phase III TH3RESA study in which treatment with the immunoconjugate trastuzumab emtansine (T-DM1) was compared against the treatment of physician's choice in roughly 600 women with previously treated HER2-positive metastatic breast cancer.

The first results from the trial were published last year and showed significantly improved PFS with T-DM1 compared with the treatment of physician’s choice. There was also a trend for improved overall survival (OS).

In the interview, Dr Wildiers notes that the final median overall survival increased from 15.8 months with physician’s choice to 22.7 months with T-DM1 (p = 0.0007).

T-DM1 has a favourable safety profile that is consistent to prior studies, he observes. Overall the findings solidify the role of T-DM1 in the treatment of previously treated HER2-positive advanced breast cancer.

свернуть